Thursday, May 6, 2021
8:30 - 9:45  
9:45 - 10:00

Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

New developments in HBOC management
10:00 - 11:30

CHAIR: Ephrat Levy-Lahad, MD, Shaare Zedek Medical Center, Jerusalem, Israel

10:00 - 10:20

Update on therapy for breast cancer for women with BRCA1/2 pathogenic variants

Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

10:20 - 10:40

New treatments for BRCA-deficient ovarian cancer

Ursula Matulonis, MD Dana-Farber Cancer Institute, Boston, MA, USA

10:40 - 10:50

Proffered paper 1 (S7-PP1)
The First Results of the Prospective Multicenter TUBA Study Investigating Salpingectomy with Delayed Oophorectomy in BRCA Mutation Carriers

Miranda Steenbeek, MD, PhD Student, Radboud University Medical Center, Nijmegen, The Netherlands

10:50 - 11:00

Proffered paper 2 (S7-PP2)
Oral Contraceptive Use and Cancer Incidence and Mortality for BRCA1 and BRCA2 Mutation Carriers: Absolute Risk-benefit Calculation Considering Breast, Ovarian and Endometrial Cancer

Matti Rookus, Netherlands Cancer Institute, Amsterdam, The Netherlands

11:00 - 11:10

Proffered paper 3 (S7-PP3)
A Positive Oestrogen Receptor Status and Breast Cancer Survival in Nordic BRCA2 Mutation Carriers

Laufey Tryggvadóttir, MSc., Professor, University of Iceland / Icelandic Cancer Registry

11:10 - 11:30

Question and discussion period (all speakers)

Poster Session 2
11:30 - 13:00
13:00 - 14:30  
Special Interest Groups (SIGs)
14:30 - 15:30

Moderated one-hour interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of the following 2 SIGs.

SIG 3:

Rarer moderate to highly penetrant breast cancer syndromes – CDH1, PTEN, TP53, NTHL1

In this session, attendees will join the presenters in exploring clinico-pathological aspects of a set of well-known and less well-known breast and ovarian cancer susceptibility genes. Dr. Tischkowitz will focus on CDH1, Dr. Hoogerbrugge on PTEN and NTHL1 and Dr. Weitzel will discuss TP53. Attendees will be encouraged to send in specific cases in advance for discussion at the SIG.

  • Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK (session lead)

  • Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Nijmegen, The Netherlands

  • Jeffrey Weitzel, MD, City of Hope National Medical Center, Duarte, CA, USA

SIG 4:

Genetic counselling – How to expect the unexpected?

In this interactive case-based session, Dr. Hurley will explore advance concepts in genetic counselling and will show how counsellors can help clients cope with the challenges associated with discovering their genetic status.

  • Karen Hurley, PhD, Cleveland Clinic, Cleveland, OH, USA

  • Wendy McKinnon, MS, CGC, University of Vermont Cancer Center, Burlington, VT, USA

15:30 - 16:00  
Polygenic risk scores in practice
16:00 - 17:30

CHAIR: Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

16:00 - 16:20

Polygenic risk scores and the CanRisk breast and ovarian cancer risk prediction tool

Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK

16:20 - 16:40

Multifactorial breast cancer risk assessment

Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

16:40 - 16:50

Proffered paper 1 (S8-PP1)
Determining Women Preferences for Population Genetic Testing to Inform Implementation of Risk-Stratified Breast Screening

Alison Trainer, FRACP, PhD, Parkville Familial Cancer Center, Melbourne, Australia

16:50 - 17:00

Proffered paper 2 (S8-PP2)
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)

Jacques Simard, PhD, Centre de recherche CHU de Québec - Université Laval, Québec, QC, Canada

17:00 - 17:30

Question and discussion period (all speakers)